Technical and regulatory hurdles for DNA vaccines

International Journal for Parasitology

Volumn 33, Issue 5-6, 2003, Pages 457-467

  Donnelly, John ^a   Berry, Karin ^a   Ulmer, Jeffrey B ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adjuvant; DNA delivery; Safety; Toxicity; Vector

Indexed keywords

ALUMINUM PHOSPHATE; B7 ANTIGEN; BACTERIAL DNA; BUPIVACAINE; CARDIOTOXIN; CD40 LIGAND; CHEMOKINE; CHITOSAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; ENVELOPE PROTEIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; L SELECTIN; LIPID; MALARIA VACCINE; NANOPARTICLE; OLIGONUCLEOTIDE; PLASMID DNA; POLYETHYLENEIMINE; POLYLYSINE; POLYMER; POVIDONE; TUMOR ANTIGEN; UNINDEXED DRUG; VIRUS VECTOR;

VACCINATION;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CANCER; CANCER MODEL; CLINICAL TRIAL; CPG ISLAND; DENDRITIC CELL; DISEASE MODEL; DNA RECOMBINATION; DRUG APPROVAL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ESCHERICHIA COLI; EXPERIMENTAL ANIMAL; FOOD AND DRUG ADMINISTRATION; GENE GUN; GENE TARGETING; GENETIC TRANSFECTION; GENOME; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; INFECTION PREVENTION; LICENSING; LISTERIA MONOCYTOGENES; MALARIA; NONHUMAN; PRIMATE; REVIEW; SALMONELLA TYPHI; SALMONELLA TYPHIMURIUM; SHIGELLA FLEXNERI; TOXICITY TESTING; VACCINE PRODUCTION; VIRUS INFECTION;

ANIMALIA; BACTERIA (MICROORGANISMS); PRIMATES;

EID: 0038362648     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7519(03)00056-0     Document Type: Review

References (125)

1. Adami R.C., Collard W.T., Gupta S.A., Kwok K.Y., Bonadio J., Rice K.G. Stability of peptide-condensed plasmid DNA formulations. J. Pharm. Sci. 87:1998;678-683.
2. Agadjanyan M.G., Kim J.J., Trivedi N., Wilson D.M., Monzavi-Karbassi B., Morrison L.D., Nottingham L.K., Dentchev T., Tsai A., Dang K., Chalian A.A., Maldonado M.A., Williams W.V., Weiner D.B. CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo. J. Immunol. 162:1999;3417-3427.
3. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., Miller J., McClure H.M., McNicholl J.M., Moss B., Robinson H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 292:2001;69-74.
4. Bachy M., Boudet F., Bureau M., Girerd-Chambaz Y., Wils P., Scherman D., Meric C. Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse. Vaccine. 19:2001;1688-1693.
5. Barber B.H. The immunotargeting approach to adjuvant-independent subunit vaccine design. Semin. Immunol. 9:1997;293-301.
6. Barnes A.G., Barnfield C., Brew R., Klavinskis L.S. Recent developments in mucosal delivery of pDNA vaccines. Curr. Opin. Mol. Ther. 2:2000;87-93.
7. Barnett S.W., Lu S., Srivastava I., Cherpelis S., Gettie A., Blanchard J., Wang S., Mboudjeka I., Leung L., Lian Y., Fong A., Buckner C., Ly A., Hilt S., Ulmer J., Wild C.T., Mascola J.R., Stamatatos L. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75:2001;5526-5540.
8. Barouch D.H., Craiu A., Kuroda M.J., Schmitz J.E., Zheng X.X., Santra S., Frost J.D., Krivulka G.R., Lifton M.A., Crabbs C.L., Heidecker G., Perry H.C., Davies M.E., Xie H., Nickerson C.E., Steenbeke T.D., Lord C.I., Montefiori D.C., Strom T.B., Shiver J.W., Lewis M.G., Letvin N.L. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc. Natl. Acad. Sci. USA. 97:2000;4192-4197.
9. Barouch D.H., Santra S., Schmitz J.E., Kuroda M.J., Fu T.M., Wagner W., Bilska M., Craiu A., Zheng X.X., Krivulka G.R., Beaudry K., Lifton M.A., Nickerson C.E., Trigona W.L., Punt K., Freed D.C., Guan L., Dubey S., Casimiro D., Simon A., Davies M.E., Chastain M., Strom T.B., Gelman R.S., Montefiori D.C., Lewis M.G., Emini E.A., Shiver J.W., Letvin N.L. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 290:2000;486-492.
10. Barouch D.H., Craiu A., Santra S., Egan M.A., Schmitz J.E., Kuroda M.J., Fu T.M., Nam J.H., Wyatt L.S., Lifton M.A., Krivulka G.R., Nickerson C.E., Lord C.I., Moss B., Lewis M.G., Hirsch V.M., Shiver J.W., Letvin N.L. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J. Virol. 75:2001;2462-2467.
11. Barry M.A., Johnston S.A. Biological features of genetic immunization. Vaccine. 15:1997;788-791.
12. Billaut-Mulot O., Idziorek T., Loyens M., Capron A., Bahr G.M. Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost. Vaccine. 19:2001;2803-2811.
13. Boyer J.D., Chattergoon M.A., Ugen K.E., Shah A., Bennett M., Cohen A., Nyland S., Lacy K.E., Bagarazzi M.L., Higgins T.J., Baine Y., Ciccarelli R.B., Ginsberg R.S., MacGregor R.R., Weiner D.B. Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial. Clin. Immunol. 90:1999;100-107.
14. Boyer J.D., Cohen A.D., Vogt S., Schumann K., Nath B., Ahn L., Lacy K., Bagarazzi M.L., Higgins T.J., Baine Y., Ciccarelli R.B., Ginsberg R.S., MacGregor R.R., Weiner D.B. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J. Infect. Dis. 181:2000;476-483.
15. Brazolot Millan C.L., Weeratna R., Krieg A.M., Siegrist C.A., Davis H.L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. USA. 95:1998;15553-15558.
16. Briones M., Singh M., Ugozzoli M., Kazzaz J., Klakamp S., Ott G., O'Hagan D. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharm. Res. 18:2001;709-711.
17. Burger J.A., Mendoza R.B., Kipps T.J. Plasmids encoding granulocyte-macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines. Vaccine. 19:2001;2181-2189.
18. Cherpelis S., Srivastava I., Gettie A., Jin X., Ho D.D., Barnett S.W., Stamatatos L. DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques. J. Virol. 75:2001;1547-1550.
19. Chow Y.H., Huang W.L., Chi W.K., Chu Y.D., Tao M.H. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J. Virol. 71:1997;169-178.
20. Chu W., Gong X., Li Z., Takabayashi K., Ouyang H., Chen Y., Lois A., Chen D., Li G., Karin M., Raz E. DNA PKcs is required for activation of innate immunity by immunostimulatory DNA. Cell. 103:2000;909-918.
21. Condon C., Watkins S.C., Celluzzi C.M., Thompson K., Falo L.D. Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2:1996;1122-1128.
22. Conry R.M., Widera G., Lobuglio A.F., Fuller J.T., Moore S.E., Barlow D.L., Turner J., Curiel D.T. Selected strategies to augment polynucleotide immunization. Gene Ther. 3:1996;67-74.
23. Cox G., Zamb T.J., Babiuk L.A. Bovine herpesvirus-1 - immune-responses in mice and cattle injected with plasmid DNA. J. Virol. 67:1993;5664-5667.
24. Cui Z., Mumper R.J. Chitosan-based nanoparticles for topical genetic immunization. J. Controlled Release. 75:2001;409-419.
25. Daheshia M., Kuklin N., Manickan E., Chun S., Rouse B.T. Immune induction and modulation by topical ocular administration of plasmid DNA encoding antigens and cytokines. Vaccine. 16:1998;1103-1110.
26. Darji A., zur Lage S., Garbe A.I., Chakraborty T., Weiss S. Oral delivery of DNA vaccines using attenuated Salmonella typhimurium as carrier. FEMS Immunol. Med. Microbiol. 27:2000;341-349.
27. Davis H.L., Michel M.L., Mancini M., Schleef M., Whalen R.G. Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. Vaccine. 12:1994;1503-1509.
28. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M., Weeranta R. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen [published erratum appears in J Immunol 1999 Mar 1;162(5):3103]. J. Immunol. 160:1999;870-876.
29. Denis-Mize K.S., Dupuis M., MacKichan M.L., Singh M., Doe B., O'Hagan D., Ulmer J.B., Donnelly J.J., McDonald D.M., Ott G. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. 7:2000;2105-2112.
30. Dietrich G., Kolb-Maurer A., Spreng S., Schartl M., Goebel W., Gentschev I. Gram-positive and Gram-negative bacteria as carrier systems for DNA vaccines. Vaccine. 19:2001;2506-2512.
31. Doe B., Selby M., Barnett S., Baenziger J., Walker C.M. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc. Natl. Acad. Sci. USA. 93:1996;8578-8583.
32. Donnelly J.J., Friedman A., Martinez D., Montgomery D.L., Shiver J.W., Motzel S.L., Ulmer J.B., Liu M.A. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med. 1:1995;583-587.
33. Donnelly J.J., Martinez D., Jansen K.U., Ellis R.W., Montgomery D.L., Liu M.A. Protection against papillomavirus with a polynucleotide vaccine. J. Infect. Dis. 173:1996;314-320.
34. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu. Rev. Immunol. 15:1997;617-648.
35. Drew D.R., Boyle J.S., Lew A.M., Lightowlers M.W., Chaplin P.J., Strugnell R.A. The comparative efficacy of CTLA-4 and L-selectin targeted DNA vaccines in mice and sheep. Vaccine. 19:2001;4417-4428.
36. Dubensky T.W. Jr, Driver D.A., Polo J.M., Belli B.A., Latham E.M., Ibanez C.E., Chada S., Brumm D., Banks T.A., Mento S.J., Jolly D.J., Chang S.M. Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J. Virol. 70:1996;508-519.
37. Eo S.K., Lee S., Kumaraguru U., Rouse B.T. Immunopotentiation of DNA vaccine against herpes simplex virus via co- delivery of plasmid DNA expressing CCR7 ligands. Vaccine. 19:2001;4685-4693.
38. Erbacher P., Bettinger T., Belguise-Valladier P., Zou S., Coll J.L., Behr J.P., Remy J.S. Transfection and physical properties of various saccharide, poly(ethylene glycol), and antibody-derivatized polyethylenimines (PEI). J. Gene Med. 1:1999;210-222.
39. Fan H., Lin Q., Morrissey G.R., Khavari P.A. Immunization via hair follicles by topical application of naked DNA to normal skin. Nat. Biotechnol. 17:1999;870-872.
40. Fields R.C., Shimizu K., Mule J.J. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 95:1998;9482-9487.
41. Frankel F.R., Hegde S., Lieberman J., Paterson Y. Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector. J. Immunol. 155:1995;4775-4782.
42. Fu T.M., Ulmer J.B., Caulfield M.J., Deck R.R., Friedman A., Wang S., Liu X., Donnelly J.J., Liu M.A. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol. Med. 3:1997;362-371.
43. Fu T.M., Guan L., Friedman A., Ulmer J.B., Liu M.A., Donnelly J.J. Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens. Vaccine. 16:1998;1711-1717.
44. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., Robinson H.L. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA. 90:1993;11478-11482.
45. Garren H., Ruiz P.J., Watkins T.A., Fontoura P., Nguyen L.T., Estline E.R., Hirschberg D.L., Steinman L. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity. 15:2001;15-22.
46. Gellin B.G., Greenberg R.N., Hart R.H., Bertino J.S. Jr, Stein D.H., Deloria M.A., Clements-Mann M.L. Immunogenicity of two doses of yeast recombinant hepatitis B vaccine in healthy older adults. J. Infect. Dis. 175:1997;1494-1497.
47. Gentschev I., Dietrich G., Spreng S., Kolb-Maurer A., Brinkmann V., Grode L., Hess J., Kaufmann S.H., Goebel W. Recombinant attenuated bacteria for the delivery of subunit vaccines. Vaccine. 19:2001;2621-2628.
48. Gramzinski R.A., Millan C.L., Obaldia N., Hoffman S.L., Davis H.L. Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. Mol. Med. 4:1998;109-118.
49. Gregoriadis G., Saffie R., de Souza J.B. Liposome-mediated DNA vaccination. FEBS Lett. 402:1997;107-110.
50. Haas J., Park E.C., Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 6:1996;315-324.
51. Hanlon L., Argyle D., Bain D., Nicolson L., Dunham S., Golder M.C., McDonald M., McGillivray C., Jarrett O., Neil J.C., Onions D.E. Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors. J. Virol. 75:2001;8424-8433.
52. Hariharan M.J., Driver D.A., Townsend K., Brumm D., Polo J.M., Belli B.A., Catton D.J., Hsu D., Mittelstaedt D., McCormack J.E., Karavodin L., Dubensky T.W. Jr, Chang S.M., Banks T.A. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J. Virol. 72:1998;950-958.
53. Hartikka J., Bozoukova V., Ferrari M., Sukhu L., Enas J., Sawdey M., Wloch M.K., Tonsky K., Norman J., Manthorpe M., Wheeler C.J. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine. 19:2001;1911-1923.
54. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A Toll-like receptor recognizes bacterial DNA. Nature. 408:2000;740-745.
55. Huang A.Y., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:1994;961-965.
56. Iwasaki A., Stiernholm B.J., Chan A.K., Berinstein N.L., Barber B.H. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J. Immunol. 158:1997;4591-4601.
57. Jansen K.U., Rosolowsky M., Schultz L.D., Markus H.Z., Cook J.C., Donnelly J.J., Martinez D., Ellis R.W., Shaw A.R. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine. 13:1995;1509-1514.
58. Jones D.H., Corris S., McDonald S., Clegg J.C., Farrar G.H. Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine. 15:1997;814-817.
59. Kim J.J., Yang J., Manson K.H., Weiner D.B. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants. Vaccine. 19:2001;2496-2505.
60. King C.A., Spellerberg M.B., Zhu D., Rice J., Sahota S.S., Thompsett A.R., Hamblin T.J., Radl J., Stevenson F.K. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med. 4:1998;1281-1286.
61. Klavinskis L.S., Gao L., Barnfield C., Lehner T., Parker S. Mucosal immunization with DNA-liposome complexes. Vaccine. 15:1997;818-820.
62. Klinman D.M., Barnhart K.M., Conover J. CpG motifs as immune adjuvants. Vaccine. 17:1999;19-25.
63. Krieg A.M. CpG oligonucleotides as immune adjuvants. Ernst Schering Res Found Workshop. 2000;105-118.
64. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
65. Le T.P., Coonan K.M., Hedstrom R.C., Charoenvit Y., Sedegah M., Epstein J.E., Kumar S., Wang R., Doolan D.L., Maguire J.D., Parker S.E., Hobart P., Norman J., Hoffman S.L. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine. 18:2000;1893-1901.
66. Logan J.J., Bebok Z., Walker L.C., Peng S., Felgner P.L., Siegal G.P., Frizzell R.A., Dong J., Howard M., Matalon S., Duvall M., Sorscher E.J. Cationic lipids for reporter gene and CFTR transfer to rat pulmonary epithelium. Gene Ther. 2:1995;38-49.
67. Lopez-Macias C., Lopez-Hernandez M.A., Gonzalez C.R., Isibasi A., Ortiz-Navarrete V. Induction of antibodies against Salmonella typhi OmpC porin by naked DNA immunization. Ann. N.Y. Acad. Sci. 772:1995;285-288.
68. Lunsford L., McKeever U., Eckstein V., Hedley M.L. Tissue distribution and persistence in mice of plasmid DNA encapsulated in a PLGA-based microsphere delivery vehicle. J. Drug Target. 8:2000;39-50.
69. MacGregor R.R., Boyer J.D., Ciccarelli R.B., Ginsberg R.S., Weiner D.B. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I Env/Rev vaccine in HIV-infected recipients: follow-up data [In Process Citation]. J. Infect. Dis. 181:2000;406.
70. MacGregor R.R., Boyer J.D., Ugen K.E., Lacy K.E., Gluckman S.J., Bagarazzi M.L., Chattergoon M.A., Baine Y., Higgins T.J., Ciccarelli R.B., Coney L.R., Ginsberg R.S., Weiner D.B. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response [see comments]. J. Infect. Dis. 178:1998;92-100.
71. MacLaughlin F.C., Mumper R.J., Wang J., Tagliaferri J.M., Gill I., Hinchcliffe M., Rolland A.P. Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J. Controlled Release. 56:1998;259-272.
72. Mahato R.I., Anwer K., Tagliaferri F., Meaney C., Leonard P., Wadhwa M.S., Logan M., French M., Rolland A. Biodistribution and gene expression of lipid/plasmid complexes after systemic administration. Hum. Gene Ther. 9:1998;2083-2099.
73. Manam S., Ledwith B.J., Barnum A.B., Troilo P.J., Pauley C.J., Harper L.B., Griffiths T.G. II, Niu Z., Denisova L., Follmer T.T., Pacchione S.J., Wang Z., Beare C.M., Bagdon W.J., Nichols W.W. Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology. 43:2000;273-281.
74. Manickan E., Kanangat S., Rouse R.J., Yu Z., Rouse B.T. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J. Leukocyte Biol. 61:1997;125-132.
75. McCluskie M.J., Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161:1998;4463-4466.
76. McCluskie M.J., Chu Y., Xia J.L., Jessee J., Gebyehu G., Davis H.L. Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA. Antisense Nucleic Acid Drug Dev. 8:1998;401-414.
77. Mollenkopf H., Dietrich G., Kaufmann S.H. Intracellular bacteria as targets and carriers for vaccination. Biol. Chem. 382:2001;521-532.
78. Montgomery D.L., Donnelly J.J., Shiver J.W., Liu M.A., Ulmer J.B. Protein expression in vivo by injection of polynucleotides. Curr. Opin. Biotechnol. 5:1994;505-510.
79. Mumper R.J., Duguid J.G., Anwer K., Barron M.K., Nitta H., Rolland A.P. Polyvinyl derivatives as novel interactive polymers for controlled gene delivery to muscle. Pharm. Res. 13:1996;701.
80. Nabel G.J., Yang Z.Y., Nabel E.G., Bishop K., Marquet M., Felgner P.L., Gordon D., Chang A.E. Direct gene transfer for treatment of human cancer. Ann. N.Y. Acad. Sci. 772:1995;227-231.
81. Nabel G.J., Gordon D., Bishop D.K., Nickoloff B.J., Yang Z.Y., Aruga A., Cameron M.J., Nabel E.G., Chang A.E. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl. Acad. Sci. USA. 93:1996;15388-15393.
82. Nishikawa M., Takemura S., Takakura Y., Hashida M. Targeted delivery of plasmid DNA to hepatocytes in vivo: optimization of the pharmacokinetics of plasmid DNA/galactosylated poly(L-lysine) complexes by controlling their physicochemical properties. J. Pharmacol. Exp. Ther. 287:1998;408-415.
83. O'Hagan D., Singh M., Ugozzoli M., Wild C., Barnett S., Chen M., Otten G.R., Ulmer J.B. Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines. J. Virol. 75:2001;9037-9043.
84. Orson F.M., Kinsey B.M., Hua P.J., Bhogal B.S., Densmore C.L., Barry M.A. Genetic immunization with lung-targeting macroaggregated polyethyleneimine-albumin conjugates elicits combined systemic and mucosal immune responses. J. Immunol. 164:2000;6313-6321.
85. Otten G.R., Chen M., Doe B., Kazzaz J., Lian Y., Liu H.M., Leung L., Ott G., Polo J.M., Shaefer M., Selby M., Singh M., Sun Y., Ugozzoli M., zur Megede J., Lewis M., Miller N., Widera G., Barnett S., Donnelly J.J., O'Hagan D., Ulmer J.B. Delivery technologies enhance plasmid DNA vaccination in a rhesus macaque model for HIV. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL. 2001.
86. Parker S.E., Ducharme S., Norman J., Wheeler C.J. Tissue distribution of the cytofectin component of a plasmid-DNA/cationic lipid complex following intravenous administration in mice. Hum. Gene Ther. 8:1997;393-401.
87. Perales M.A., Schwartz D.H., Fabry J.A., Lieberman J. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10:1995;27-35.
88. Perrie Y., Frederik P.M., Gregoriadis G. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine. 19:2001;3301-3310.
89. Pertmer T.M., Eisenbraun M.D., McCabe D., Prayaga S.K., Fuller D.F., Haynes J.R. Gene gun-based nucleic-acid immunization - elicitation of humoral and cytotoxic t-lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine. 13:1995;1427-1430.
90. Porgador A., Irvine K.R., Iwasaki A., Barber B.H., Restifo N.P., Germain R.N. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J. Exp. Med. 188:1998;1075-1082.
91. Rizzuto G., Cappelletti M., Maione D., Savino R., Lazzaro D., Costa P., Mathiesen I., Cortese R., Ciliberto G., Laufer R., La Monica N., Fattori E. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc. Natl. Acad. Sci. USA. 96:1999;6417-6422.
92. Robinson H.L., Hunt L.A., Webster R.G. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine. 11:1993;957-960.
93. Rodriguez F., Zhang J., Whitton J.L. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 71:1997;8497-8503.
94. Rodriguez F., An L.L., Harkins S., Zhang J., Yokoyama M., Widera G., Fuller J.T., Kincaid C., Campbell I.L., Whitton J.L. DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J. Virol. 72:1998;5174-5181.
95. Roy M.J., Wu M.S., Barr L.J., Fuller J.T., Tussey L.G., Speller S., Culp J., Burkholder J.K., Swain W.F., Dixon R.M., Widera G., Vessey R., King A., Ogg G., Gallimore A., Haynes J.R., Heydenburg Fuller D. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine. 19:2000;764-778.
96. Saikh K.U., Sesno J., Brandler P., Ulrich R.G. Are DNA-based vaccines useful for protection against secreted bacterial toxins? Tetanus toxin test case. Vaccine. 16:1998;1029-1038.
97. Sato Y., Roman M., Tighe H., Lee D., Corr M., Nguyen M.D., Silverman G.J., Lotz M., Carson D.A., Raz E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 273:1996;352-354.
98. Selby M., Goldbeck C., Pertile T., Walsh R., Ulmer J. Enhancement of DNA vaccine potency by electroporation in vivo. J. Biotechnol. 83:2000;147-152.
99. Shata M.T., Hone D.M. Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity. J. Virol. 75:2001;9665-9670.
100. Shata M.T., Stevceva L., Agwale S., Lewis G.K., Hone D.M. Recent advances with recombinant bacterial vaccine vectors. Mol. Med. Today. 6:2000;66-71.
101. Shata M.T., Reitz M.S. Jr, De Vico A.L., Lewis G.K., Hone D.M. Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine. 20:2001;623-629.
102. Shimizu K., Fields R.C., Giedlin M., Mule J.J. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad. Sci. USA. 96:1999;2268-2273.
103. Silva C.L., Bonato V.L., Lima V.M. DNA encoding individual mycobacterial antigens protects mice against tuberculosis. Braz. J. Med. Biol. Res. 32:1999;231-234.
104. Singh M., Briones M., Ott G., O'Hagan D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. USA. 97:2000;811-816.
105. Sizemore D.R., Branstrom A.A., Sadoff J.C. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science. 270:1995;299-302.
106. Smith H.A., Klinman D.M. The regulation of DNA vaccines. Curr. Opin. Biotechnol. 12:2001;299-303.
107. Spellerberg M.B., Zhu D., Thompsett A., King C.A., Hamblin T.J., Stevenson F.K. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J. Immunol. 159:1997;1885-1892.
108. Spreng S., Dietrich G., Niewiesk S., ter Meulen V., Gentschev I., Goebel W. Novel bacterial systems for the delivery of recombinant protein or DNA. FEMS Immunol. Med. Microbiol. 27:2000;299-304.
109. Tacket C.O., Roy M.J., Widera G., Swain W.F., Broome S., Edelman R. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine. 17:1999;2826-2829.
110. Tang D.C., De Vit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature. 356:1992;152-154.
111. Ugen K.E., Nyland S.B., Boyer J.D., Vidal C., Lera L., Rasheid S., Chattergoon M., Bagarazzi M.L., Ciccarelli R., Higgins T., Baine Y., Ginsberg R., Macgregor R.R., Weiner D.B. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine. 16:1998;1818-1821.
112. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein [see comments]. Science. 259:1993;1745-1749.
113. Ulmer J., Deck R.R., Dewitt C.M., Donnhly J.I., Liu M.A. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology. 89:1996;59-67.
114. Ulmer J.B., DeWitt C.M., Chastain M., Friedman A., Donnelly J.J., McClements W.L., Caulfield M.J., Bohannon K.E., Volkin D.B., Evans R.K. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine. 18:1999;18-28.
115. Wang B., Ugen K.E., Srikantan V., Agadjanyan M.G., Dang K., Refaeli Y., Sato A.I., Boyer J., Williams W.V., Weiner D.B. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA. 90:1993;4156-4160.
116. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., Jones T.R., Hobart P., Margalith M., Ng J., Weiss W.R., Sedegah M., de Taisne C., Norman J.A., Hoffman S.L. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 282:1998;476-480.
117. Wang R., Epstein J., Baraceros F.M., Gorak E.J., Charoenvit Y., Carucci D.J., Hedstrom R.C., Rahardjo N., Gay T., Hobart P., Stout R., Jones T.R., Richie T.L., Parker S.E., Doolan D.L., Norman J., Hoffman S.L. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc. Natl. Acad. Sci. USA. 98:2001;10817-10822.
118. Weeratna R., Brazolot Millan C.L., Krieg A.M., Davis H.L. Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. 8:1998;351-356.
119. Weiss R., Durnberger J., Mostbock S., Scheiblhofer S., Hartl A., Breitenbach M., Strasser P., Dorner F., Livey I., Crowe B., Thalhamer J. Improvement of the immune response against plasmid DNA encoding OspC of Borrelia by an ER-targeting leader sequence. Vaccine. 18:1999;815-824.
120. Wells D.J., Maule J., McMahon J., Mitchell R., Damien E., Poole A., Wells K.E. Evaluation of plasmid DNA for in vivo gene therapy: factors affecting the number of transfected fibers. J. Pharm. Sci. 87:1998;763-768.
121. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S.W., Chen M., Leung L., Otten G.R., Thudium K., Selby M.J., Ulmer J.B. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol. 164:2000;4635-4640.
122. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., Felgner P.L. Direct gene transfer into mouse muscle in vivo. Science. 247:1990;1465-1468.
123. Wu G.Y., Wilson J.M., Shalaby F., Grossman M., Shafritz D.A., Wu C.H. Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in Nagase rats. J. Biol. Chem. 266:1991;14338-14342.
124. Xiang Z., Ertl H.C. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity. 2:1995;129-135.
125. zur Megede J., Chen M.C., Doe B., Schaefer M., Greer C.E., Selby M., Otten G.R., Barnett S.W. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J. Virol. 74:2000;2628-2635.